ResultsIQ › Latest results › Max Healthcare Institute Limited
Max Healthcare Institute Limited strategy deck summary
NSE: MAXHEALTH · BSE: 543220
Strategy deck of 13 Nov 2026, summarised by AI from the filing.
Max Healthcare's Q2 FY27 net revenue rose 18% to ₹3,055 cr, with operating EBITDA of ₹820 cr at 26.8% of net revenue.
Key takeaways
- Q2 revenue Net revenue was ₹3,055 cr (Q2 FY26: ₹2,580 cr, +18%) and operating EBITDA ₹820 cr at 26.8% of net revenue.
- Bhubaneswar Kalinga Hospital became a subsidiary on May 18, 2026 and was rebranded Max Super Speciality Hospital, Bhubaneswar.
- Digital Digital revenue through online marketing and web-based appointments was ~33% of overall revenue in H1 FY27.
- Receivables DSO lengthened to 93 days at Sep'26 from 87 days at Mar'26.
Max Healthcare Institute Limited Q2 FY27 results
As filed: Revenue ₹2,569 cr (+20% year on year), EBITDA ₹711 cr (+24% year on year), PAT ₹414 cr (−16% year on year), EBITDA margin 27.7% (+76 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹2,366 cr (+17% year on year), EBITDA ₹598 cr (+15% year on year), PAT ₹323 cr (+5% year on year), EBITDA margin 25.3% (−45 bps). Score 37 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 45 bps year on year. Profit fell 6% from last quarter. Revenue rose ₹338 cr on a year ago, against ₹485 cr the year before. Share price after the results: +3.0% in 29 days (Nifty 500: −3.4%).
- Q4 FY26: Revenue ₹2,143 cr (+12% year on year), EBITDA ₹606 cr (+18% year on year), PAT ₹342 cr (+7% year on year), EBITDA margin 28.3% (+149 bps). Score 43 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 149 bps year on year. Revenue rose ₹233 cr on a year ago, against ₹487 cr the year before. Share price after the results: +0.3% in 29 days (Nifty 500: +2.4%).
- Q3 FY26: Revenue ₹2,068 cr (+11% year on year), EBITDA ₹538 cr (+8% year on year), PAT ₹301 cr (+8% year on year), EBITDA margin 26.0% (−73 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit before exceptional items growth was below it. EBITDA margin fell 73 bps year on year. Revenue fell 3% from last quarter. Revenue rose ₹200 cr on a year ago, against ₹533 cr the year before. Share price after the results: +1.6% in 29 days (Nifty 500: −4.5%).
- Q2 FY26: Revenue ₹2,135 cr (+25% year on year), EBITDA ₹575 cr (+27% year on year), PAT ₹491 cr (+74% year on year), EBITDA margin 26.9% (+51 bps). Score 69 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well above it. EBITDA margin rose 51 bps year on year. Tax rate -10%. Consolidated profit +74% but standalone -31%. Revenue rose ₹428 cr on a year ago, more than the ₹344 cr it added the year before. Share price after the results: −2.0% in 28 days (Nifty 500: −0.5%).
- Q1 FY26: Revenue ₹2,028 cr (+31% year on year), EBITDA ₹522 cr (+35% year on year), PAT ₹308 cr (+31% year on year), EBITDA margin 25.7% (+66 bps). Score 83 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 66 bps year on year. Profit fell 3% from last quarter. Revenue rose ₹485 cr on a year ago, more than the ₹258 cr it added the year before. Share price after the results: −6.1% in 30 days (Nifty 500: +2.8%).
- Q4 FY25: Revenue ₹1,910 cr (+34% year on year), EBITDA ₹512 cr (+34% year on year), PAT ₹319 cr (+27% year on year), EBITDA margin 26.8% (−4 bps). Score 78 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin was flat year on year. Consolidated profit +27% but standalone -27%. Revenue rose ₹487 cr on a year ago, more than the ₹208 cr it added the year before. Share price after the results: −2.1% in 30 days (Nifty 500: −0.4%).
- Q3 FY25: Revenue ₹1,868 cr (+40% year on year), EBITDA ₹500 cr (+30% year on year), PAT ₹239 cr (+6% year on year), EBITDA margin 26.8% (−215 bps). Score 71 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit before exceptional items growth was below it. EBITDA margin fell 215 bps year on year.
Past price moves after results do not indicate future moves. Not a recommendation.
Max Healthcare Institute Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (3 Nov 2026)
- Q1 FY27: Earnings call (14 Aug 2026)
- Q4 FY26: Earnings call (22 May 2026)
- Q3 FY26: Earnings call (6 Feb 2026)
- Q2 FY26: Earnings call (17 Nov 2025)
- Q1 FY26: Earnings call (14 Aug 2025)
- Q4 FY25: Earnings call (21 May 2025)
- Other events: Strategy deck (13 Nov 2026), Strategy deck (17 Aug 2026), AGM (30 Jul 2026), Strategy deck (26 May 2026), Strategy deck (20 Feb 2026), Strategy deck (7 Feb 2026), Strategy deck (19 Nov 2025), Strategy deck (17 Nov 2025), Strategy deck (29 Aug 2025), AGM (30 Jul 2025), Strategy deck (31 May 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.